IL-13 as a novel growth factor in CTCL.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

1. CDK9 recruits HUWE1 to degrade RARα and offers therapeutic opportunities for cutaneous T-cell lymphoma.Nature communications · 2024
   Article
2. Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma.JCI insight · 2023
   Article
3. Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells.Molecular medicine (Cambridge, Mass.) · 2017
   Article
4. Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.Cancer discovery · 2016
   Article
5. Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets.BioMed research international · 2016
   Review

Corrections and comments

• Comment on
  Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation.2015

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as